| Literature DB >> 35448506 |
Peng Lei1,2,3, Chijioke Chukwudi1,2,3, Prabh R Pannu1,2,3, Shijie He1,2,3, Nima Saeidi1,2,3.
Abstract
Roux-en-Y gastric bypass (RYGB) surgery potently improves obesity and a myriad of obesity-associated co-morbidities including type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). Time-series omics data are increasingly being utilized to provide insight into the mechanistic underpinnings that correspond to metabolic adaptations in RYGB. However, the conventional computational biology methods used to interpret these temporal multi-dimensional datasets have been generally limited to pathway enrichment analysis (PEA) of isolated pair-wise comparisons based on either experimental condition or time point, neither of which adequately capture responses to perturbations that span multiple time scales. To address this, we have developed a novel graph network-based analysis workflow designed to identify modules enriched with biomolecules that share common dynamic profiles, where the network is constructed from all known biological interactions available through the Kyoto Encyclopedia of Genes and Genomes (KEGG) resource. This methodology was applied to time-series RNAseq transcriptomics data collected on rodent liver samples following RYGB, and those of sham-operated and weight-matched control groups, to elucidate the molecular pathways involved in the improvement of as NAFLD. We report several network modules exhibiting a statistically significant enrichment of genes whose expression trends capture acute-phase as well as long term physiological responses to RYGB in a single analysis. Of note, we found the HIF1 and P53 signaling cascades to be associated with the immediate and the long-term response to RYGB, respectively. The discovery of less intuitive network modules that may have gone overlooked with conventional PEA techniques provides a framework for identifying novel drug targets for NAFLD and other metabolic syndrome co-morbidities.Entities:
Keywords: NAFLD; RNA sequencing; RYGB; graph network; systems biology; time course study
Year: 2022 PMID: 35448506 PMCID: PMC9025796 DOI: 10.3390/metabo12040318
Source DB: PubMed Journal: Metabolites ISSN: 2218-1989
Figure 1(a) Schematic of RYGB surgery. (b) Comparison of mean body weight change from baseline between Sham and RYGB groups at one day intervals for 12 weeks. (c) Comparison of plasma glucose levels (mg/dl) between RYGB, Sham, and weight-matched (WM) groups at 1 week, 1 month, and 3 month time points. (d) Histological analysis of liver slices for RYGB and both controls (Sham, WM) at 1 week, 1 month, and 3 month time points. Several of the lipid droplets are identified by the arrowheads; (e–g) MA plots showing gene expression Log2 fold change between RYGB and WM groups at each time point for all transcripts measured using RNA-seq.
Figure 2(a) Example of a dynamic trend plot (DTP) for two genes showing the Log2 fold-change (L2FC) between RYGB and WM groups at the 1 week, 1 month, and 3 month time points. (b) DTP of the top 1% scoring genes designated to each combined trend (CT) based on mean L2FC values. (c) Example for the DTP of two genes where one (MDM2) is a negative regulator of the other (TP53). (d) Frequency plot showing the number of genes that are classified as belonging to one of 18 possible trends based on the mean L2FC at each time point. (e) Frequency of genes classified as belonging to one of 9 possible combined trends (CT) where a CT represents the two original dynamic trends that are mirror images of each other along the x-axis. (f) Distribution of L2FC values between RYGB and WM at all time points. (g) Distribution of the normalized CT score for each CT.
Figure 3(a) Distribution of normalized module scores for the case where experimental RNAseq data for RYGB vs. WM liver samples compared to the control case where L2FC values for all time points are shuffled. (b) Probability–probability plots comparing the experimental and control cases for each CT.
Figure 4Sample modules enriched for genes exhibiting (a) CT-1, (b) CT-2, (c) CT-3, and (d) CT-4 dynamic behavior.